Teniposide small-cell lung cancer randomized study randomized study teniposide etoposide differences activity toxicity analogs small-cell lung cancer SCLC untreated patients SCLC patients assessable response differences groups respect extent disease median age performance status PS initial doses compounds IV days weeks inclusion patients study doses differences toxicity hematologic toxicity study overall responses complete response CR partial response PR CR compounds Median survival months patients months patients active single agents SCLC 